Sep 24, 2008 (Zacks Investment Research via COMTEX) -- OSIR | Quote | Chart | News | PowerRating -- Osiris Therapeutics, Inc. (OSIR) is a company founded to commercialize stem cell products from adult bone marrow, a readily available and non-controversial source. The company is making significant progress with stem cell therapies. The potential for Prochymal is enormous if several of the phase III trials in GvHD, Crohn's Disease, as well as early-stage programs in acute MI, COPD, ARS, and Type-1 diabetes, pan out. We are highly encouraged by what data we've seen so far. Osiris could potentially be developing a blockbuster drug in Prochymal. We are reiterating our Buy rating and $22 price target. Read the full analyst report on OSIR
http://www.tradingmarkets.com/.site/news/Stock News/1899851/
http://www.tradingmarkets.com/.site/news/Stock News/1899851/